Genome-Wide Association Study of Prostate Cancer–Specific Survival
Background: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical.
Methods: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR).
Results: We observed no significant association between genetic variants and prostate cancer survival.
Conclusions: Common genetic variants with large impact on prostate cancer survival were not observed in this study.
Impact: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes. Cancer Epidemiol Biomarkers Prev; 24(11); 1–5. ©2015 AACR.
Note: Full list of participants of The PRACTICAL Consortium is provided in the Supplementary Notes.
Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (http://cebp.aacrjournals.org/).
- Received June 11, 2015.
- Revision received July 23, 2015.
- Accepted July 28, 2015.
- ©2015 American Association for Cancer Research.
Published OnlineFirst October 10, 2015